Investors should consider buying resurgent healthcare and biotech stocks amid the AI selloff. Today, we are digging into why ...

Biotech usually torches cash and dilutes shareholders to fund the next trial. Three drugmakers flip that script, and the one ...

The drugmaker's deep pipeline, which features MariTide -- a highly promising weight-loss medicine -- should enable it to ...

Disc Medicine anticipates a U.S. Food and Drug Administration decision on bitopertin by mid-2027, with a potential launch ...

The drug and biotechnology sector has staged a notable recovery in 2026, driven by improving investor sentiment, continued ...

Exelixis (EXEL) demonstrates strong technical momentum, recently hitting a new all-time high. ・Shares are up more than 70% ...

Argenx can truly boast a pipeline-in-a-product with efgartigimod alfa. The company already markets the drug in two forms -- ...

All that has changed, and if you want to invest in growth away from AI, biotech might be where you want to be. Below, I will attempt to lay out the various macro and policy disruptions that had a ...

The company saw a 52-week high of $230.49 on Monday.

Shares of Vir Biotechnology rose after the company reported positive results from two studies for a chronic hepatitis treatment. The stock gained 16% to $14.19 in premarket trading on Monday. At ...